Genmin Lu
AstraZeneca (Australia)(AU)Alexion Pharma (Switzerland)(CH)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, Venous Thromboembolism Diagnosis and Management, Cardiac Arrhythmias and Treatments, Cardiac electrophysiology and arrhythmias
Most-Cited Works
- → Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity(2015)1,033 cited
- → Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors(2019)929 cited
- → Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors(2016)781 cited
- → A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa(2013)691 cited
- → A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors(2013)115 cited
- → A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors(2014)94 cited